Genflow Biosciences Stock Price, News & Analysis

Genflow Biosciences (LSE:GENF/OTCQB:GENFF) has secured an institutional investment of £434,083 through a binding offer for 41,341,324 Ordinary Shares at 1.05p per share. The shares will be issued after April 9, 2025, with trading admission expected around April 10, 2025.

Company Director Eric Leire intends to invest an additional £50,000 under the same terms. Following the share issuance, the company's enlarged issued share capital will comprise 391,047,942 ordinary shares.

The funding, combined with previous government grants, will support Genflow's 2025 programs, particularly a newly launched proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs. The trial will involve 28 dogs aged 10+ years, conducted with CRO Syngene, focusing on biological age estimation, muscle strength, muscle mass, mitochondrial function, coat quality, and overall health indicators over a 12-month period.

Genflow Biosciences (LSE:GENF)(OTCQB:GENFF) announced significant progress in its patent application for SIRT6 variants, aimed at preventing and treating age-related diseases. The European patent application (EP 22 808 414.1), filed on May 13, 2022, has successfully cleared the Supplementary European Search Report without additional queries from the European Patent Office.

The patent application, originally filed by the University of Rochester, The Trustees of Columbia University, and the Albert Einstein College of Medicine, focuses on SIRT6 gene/protein variants, which play important roles in DNA repair, metabolism, and longevity. The application has now advanced to the national phase of the patent process, with Genflow preparing to proceed by July 7, 2025.

Genflow Biosciences PLC (GENFF) has reported a significant change in shareholding. Jonathan Mark Swann from Rickmansworth, UK, has increased his voting rights in the company from 5.03% to 6.01%, representing 21,025,000 voting rights. The threshold was crossed on January 10, 2025, and the company was notified on January 13, 2025.

The notification indicates this change resulted from an acquisition of voting rights, with all shares being held directly. No financial instruments or similar economic instruments were reported as part of this holding. The shareholder is not controlled by any natural person or legal entity and does not control any other undertaking holding interests in Genflow Biosciences.

Genflow Biosciences PLC has reported a significant change in shareholding, with Premier Miton Group plc crossing a notification threshold on January 9, 2025. The investment firm now holds 15,147,262 voting rights, representing 4.33142% of the company's total voting rights, down from their previous position of 9.15053%.

The change was due to an acquisition or disposal of financial instruments, as reported through a standard TR-1 form. The notification was formally submitted on January 10, 2025, with Premier Fund Managers , a controlled undertaking of Premier Miton Group plc, being the entity holding the voting rights.

Genflow Biosciences has reported key developments for 2024 in their aging-focused therapeutic programs. The company's MASH program (GF-1002) is advancing to pre-IND phase, partnering with Exothera SA for GMP manufacturing of clinical lots. For Werner Syndrome (GF-1003), they've developed proprietary liver organoids from human patient cells. The Dog Aging program (GF-1004) is initiating a six-month life extension clinical trial in collaboration with Syngene, expected to complete analysis by end of 2025.

Their Sarcopenia program (GF-1005) is progressing with myoblast progenitor studies in partnership with Université libre de Bruxelles, focusing on mitochondrial dysfunction. The company received support from the Belgian Government and has strengthened its research collaborations throughout the year.

Genflow, an emerging leader in longevity research, announced it has secured €4,026,525 in non-dilutive financial support from the Wallonia region for the development of its lead gene therapy, GF-1002, aimed at treating Metabolic Associated Steatohepatitis (MASH). The support includes a €1,218,349.44 non-reimbursable research grant covering 70% of research costs and a €2,808,175.92 recoverable advance, repayable upon commercialization, funding 55% of development costs. This funding is expected to cover three years of development, with the first installment to be received as working capital. This milestone will accelerate GF-1002's clinical progress, addressing a condition with treatment options. Dr. Eric Leire, CEO, expressed gratitude for the Wallonia region's support, emphasizing its validation of Genflow's innovative gene therapy work. Further updates on GF-1002's progress will be shared in due course.

Genflow Biosciences (LSE:GENF) released its half-year report for the period ending June 30, 2024. Key developments include progress in its longevity programs for MASH and Werner Syndrome, enhanced by the FDA's encouragement to proceed with pilot proof-of-concept studies using 3-D liver organoids from Werner patients. Additionally, Genflow initiated a feasibility study with Exothera S.A. for GMP-compliant production and is selecting CROs for a dog clinical trial of GF-1004.

The company received €777,281 in grants for collaborations on sarcopenia and exosome-mRNA projects and €350,000 from the Wallonia government. Financially, Genflow raised £715,000 in equity financing, bringing cash reserves to £1,139,859, despite higher administration expenses of £1,316,368. The period's operating loss was £524,259. The company remains debt-free and expects future funding to support its R&D activities.

Genflow Biosciences (LSE:GENF, OTCQB:GENFF), a leader in longevity research, announced that all resolutions at the Annual General Meeting (AGM) held on June 27, 2024, were approved.

Genflow Biosciences has announced significant strides in its pre-clinical efforts for the development of therapeutic solutions targeting age-related diseases. The company has initiated a feasibility study with Exothera S.A., a CDMO, to ensure GMP-compliant production of clinical lots. Genflow is also in the process of selecting CROs for its upcoming dog clinical trial of GF-1004. Additionally, the FDA has provided research guidance through INTERACT, advising Genflow to proceed with pilot proof-of-concept studies for GF-1002, aimed at treating Metabolic Associated Steatohepatitis (MASH). The FDA's feedback supports the continuation of toxicology and biodistribution studies, which are important for eventual clinical trials. This progress highlights Genflow's commitment to advancing its therapeutic pipeline.